AlzeCure Pharma AB (publ) (FN STO: ALZCUR), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer’s disease and pain, today announced that the company will participate and present at Swiss Nordic Bio 2026 in Zurich on October 1, a partnering and investor conference connecting Nordic, Swiss and Austrian companies in biotech, medtech and pharma with global investors and industry representatives.
At the event, CEO Martin Jönsson will give an updated view of the company following the recently signed collaboration and outlicensing agreements with US-based Eli Lilly and Denmark-based QuantumCell ApS, both relating to AlzeCure's Alzheimer's programs, and hold one-on-one meetings with investors and potential partners.
Date: October 1, 2026
Location: Zurich, Switzerland
Organizers: Business Sweden and Pareto Securities, in cooperation with Swiss and Austrian partners
The Swiss Nordic Bio conference gathers around 200 participants, including more than 70 investors, and features more than 40 company presentations as well as over 400 one-on-one partnering meetings.
